Short answer
PALB2 is a hereditary cancer gene often included on broad breast, ovarian, pancreatic, and multigene cancer panels. A pathogenic or likely pathogenic PALB2 result can change breast screening and family-testing discussions, and may raise pancreatic or ovarian risk questions depending on the person and family history. A PALB2 VUS is different: it is uncertain and should not be treated like a confirmed harmful variant.
How to read the result
| Report wording | Practical meaning | What to ask next |
|---|---|---|
| Pathogenic or likely pathogenic PALB2 variant | The lab found a PALB2 change with enough evidence to be handled as harmful. | What breast screening, prevention, pancreatic-risk review, and family testing should be discussed? |
| PALB2 variant of uncertain significance | The lab found a PALB2 change, but the cancer-risk meaning is not established. | How should care be based on personal and family history while the variant remains uncertain? |
| Negative PALB2 result | No reportable PALB2 variant was found in the test performed. | Were other hereditary cancer genes tested, and was there a known family variant? |
| Tumor-only PALB2 finding | The result may reflect a change in cancer tissue rather than inherited DNA. | Is separate germline testing needed before relatives are told to test? |
Cancer-risk questions to clarify
- Breast cancer risk is the main PALB2 discussion, but the exact plan depends on age, sex, personal cancer history, and family history.
- Pancreatic cancer risk may be relevant, especially when pancreatic cancer appears in the family.
- Ovarian cancer risk is more uncertain than BRCA1/2 risk and should be discussed with a genetics-aware clinician rather than assumed from a headline.
- Male breast cancer, prostate cancer, and other cancer claims should be anchored to the specific report and current guidance.
Questions to bring to counseling
- Is this a germline result from blood, saliva, cheek cells, or another normal sample?
- What is the exact PALB2 variant notation and classification?
- Was PALB2 found on a focused hereditary breast cancer panel, a broad cancer panel, or tumor testing?
- Which relatives should be offered targeted testing, and should an affected relative be tested first?
- What parts of my screening plan come from the PALB2 result, and what parts come from family history alone?
Related guides: BRCA testing vs broad cancer panels, BRCA VUS result interpretation, hereditary cancer genetic testing, and tumor genomic vs inherited genetic testing.
When follow-up matters more
Follow-up matters more when the variant class is unclear, family history is strong, the result is a VUS, or the cancer history does not match the current screening plan. That is the point to confirm whether genetics counseling, tumor testing, or family testing changes the next step.
When the result needs context
A general lab reference can explain PALB2, but it cannot tell you whether the finding came from germline DNA, tumor-only testing, or a broader panel. The exact variant, family pattern, and prior test type matter more than the gene name alone.
FAQ
Is PALB2 mainly a breast-cancer gene?
PALB2 is most often discussed for breast cancer risk, but pancreatic and ovarian risk questions may also matter in some families.
Does a PALB2 VUS change care?
No. A variant of uncertain significance should not be managed like a confirmed pathogenic variant.
Does a negative PALB2 result rule out inherited risk?
Not always. A negative result can still be uninformative if the family history remains strong or the test was not targeted to a known familial variant.
Does tumor-only PALB2 prove inherited risk?
No. A tumor-only finding does not by itself prove that the variant is inherited.
Should relatives be tested?
If a familial pathogenic PALB2 variant is known, targeted family testing may be appropriate.
What should counseling clarify first?
The exact variant, family cancer pattern, specimen type, and whether prior tumor findings were confirmed in germline DNA.